Association of PPARγ allelic variation, osteoprotegerin and abdominal aortic aneurysm

Clinical Endocrinology

Volumn 72, Issue 1, 2010, Pages 128-132

  Moran, Corey S ^a   Clancy, Paula ^a   Biros, Erik ^a   Blanco Martin, Bernardo ^a   McCaskie, Pamela ^b   Palmer, Lyle J ^b   Coomans, Danny ^a   Norman, Paul E ^c   Golledge, Jonathan ^a  

^a JAMES COOK UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYTOSINE; OSTEOPROTEGERIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; THIOURACIL; TNFRSF11B PROTEIN, HUMAN;

ABDOMINAL AORTA ANEURYSM; AGE; AORTA; ARTICLE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL ASSESSMENT; CORRELATIONAL STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DNA POLYMORPHISM; DYSLIPIDEMIA; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ULTRASOUND; ABDOMINAL AORTA; AGED; ALLELE; BLOOD; COHORT ANALYSIS; DISEASE COURSE; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; ALLELES; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; COHORT STUDIES; DISEASE PROGRESSION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; OSTEOPROTEGERIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA;

EID: 72249098114     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2009.03615.x     Document Type: Article

References (29)

1. Golledge, J., Muller, J., Daugherty, A. et al. (2006) Abdominal aortic aneurysm: pathogenesis and implications for management. Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 2605 2613. (Pubitemid 44777272)
2. Moran, C.S., McCann, M., Karan, M. et al. (2005) Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation, 111, 3119 3125.
3. Moran, C.S., Cullen, B., Campbell, J.H. et al. (2008) Interaction between angiotensin II, osteoprotegerin and peroxisome proliferator-activated receptorγ in abdominal aortic aneurysm. Journal of Vascular Research, 46, 209 217.
4. Straus, D.S. Glass, C.K. (2007) Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends in Immunology, 28, 551 558.
5. Appel, S., Mirakaj, V., Bringmann, A. et al. (2005) PPAR-gamma agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-kappaB pathways. Blood, 106, 3888 3894.
6. Duan, S.Z., Usher, M.G. Mortensen, R.M. (2008) Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circulation Research, 102, 283 294.
7. Hanefeld, M., Marx, N., Pfützner, A. et al. (2007) Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. Journal of the American College of Cardiology, 49, 290 297.
8. Knouff, C. Auwerx, J. (2004) Peroxisome proliferator-activated receptor gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocrine Reviews, 25, 899 918.
9. Werman, A., Hollenberg, A., Solanes, G. et al. (1997) Ligand-independent activation domain in the N Terminus of peroxisome proliferator-activated receptor gamma. Journal of Biological Chemistry, 272, 20230 20235.
10. Deeb, S.S., Fajas, L., Nemoto, M. et al. (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature Genetics, 20, 284 287.
11. Tai, E.S., Corella, D., Deurenberg-Yap, M. et al. (2004) Differential effects of the C1431T and Pro12Ala PPARγ gene variants on plasma lipids and diabetes risk in and Asian population. Journal of Lipid Research, 45, 674 685.
12. Kolehmainen, M., Uusitupa, M.I.J., Alhava, E. et al. (2003) Effect of the Pro12Ala polmorphism in the PPARγ 2 gene on the expression of PPARγ target genes in adipose tissue of massively obese subjects. Journal of Clinical Endocrinology and Metabolism, 88, 1717 1722.
13. Sherry, S.T., Ward, M.H., Kholodov, M. et al. (2001) dbSNP: the NCBI database of genetic variation." Nucleic Acids Research, 29, 308 311.
14. Yen, C.J., Beamer, B.A., Negri, C. et al. (1997) Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochemical and Biophysical Research Communications, 241, 270 274.
15. Norman, P.E., Flicker, L., Almeida, O.P. et al. (2008) Cohort profile: the Health In Men Study (HIMS). International Journal of Epidemiology, 38, 48 52.
16. Golledge, J., Clancy, P., Jamrozik, K. et al. (2007) Obesity, adipokines, and abdominal aortic aneurysm: Health in Men study. Circulation, 116, 2275 2279.
17. Golledge, J. Norman, P.E. (2008) Relationship between two sequence variations in the gene for peroxisome proliferator-activated receptor-gamma and plasma homocysteine concentration. Health in men study. Human Genetics, 123, 35 40.
18. Clancy, P., Oliver, L., Jayalath, R. et al. (2006) Assessment of a serum assay for quantification of abdominal aortic calcification. Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 2574 2576.
19. Wigginton, J.E., Cutler, D.J. Abecasis, G.R. (2005) A Note on exact Tests of Hardy-Weinberg Equilibrium. American Journal of Human Genetics, 76, 887 893.
20. Carter, K.W., McCaskie, P.A. Palmer, L.J. (2006) JLIN: a java based linkage disequilibrium plotter. BMC Bioinformatics, 7, 60.
21. Stephens, M., Smith, N. Donnelly, P. (2001) A new statistical method for haplotype reconstruction from population data. American Journal of Human Genetics, 68, 978 989.
22. Brady, A.R., Thompson, S.G., Fowkes, F.G. et al. (2004) UK Small Aneurysm Trial Participants. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation, 110, 16 21.
23. Golledge, J., Karan, M., Moran, C.S. et al. (2008) Reduced expansion rate of abdominal aortic aneurysms in patients with diabetes may be related to aberrant monocyte-matrix interactions. European Heart Journal, 29, 665 672.
24. Golledge, J., McCann, M., Mangan, S. et al. (2004) Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke, 35, 1636 1641.
25. Kiechl, S., Schett, G., Wenning, G. et al. (2004) Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation, 109, 2175 2180.
26. Golledge, J., Muller, J., Shephard, N. et al. (2007) Association between osteopontin and human abdominal aortic aneurysm. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 655 660. (Pubitemid 46263414)
27. Bennett, B.J., Scatena, M., Kirk, E.A. et al. (2006) Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 2117 2124.
28. Morony, S., Tintut, Y., Zhang, Z. et al. (2008) Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation, 117, 411 420.
29. Rhee, E.J., Oh, K.W., Yun, E.J. et al. (2007) The association of Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma gene with serum osteoprotegerin levels in healthy Korean women. Experimental & Molecular Medicine, 39, 696 704.